在杜皮卢马布治疗后,在无形性皮炎患者中,黄金葡萄球菌的快速减少
Eric L Simpson1, Patrick M Schlievert2, Takeshi Yoshida3
1Department of Dermatology, Oregon Health and Science University, Portland, Ore.
The Journal of allergy and clinical immunology
|June 14, 2023
概括
杜皮卢马布在3天内迅速降低了阿托皮性皮肤炎 (AD) 患者的金黄色葡萄球菌,与改善的疾病严重程度相关. 这表明2型炎症阻塞和AD中的微生物变化之间存在联系.
科学领域:
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
- 皮肤病学 皮肤病学
背景情况:
- 亚托皮炎 (AD) 是一种慢性炎症性皮肤疾病.
- 2型炎症是AD病变发生的关键驱动因素.
- 黄金葡萄球菌殖民在阿尔茨海默病中很常见,并且与疾病的严重程度有关.
研究的目的:
- 调查二型炎症抑制剂杜皮卢马布 (dupilumab) 对AD的宿主-微生物界面的影响.
- 描述在杜皮卢马布治疗后黄金葡萄球菌和宿主免疫反应的变化.
主要方法:
- 这是一项随机,双盲,安慰剂控制的研究,涉及71名中度至重度AD患者.
- 生物测试包括黄金菌量化,微生物组分析,血清生物标志物,皮肤转录组学和T细胞表型.
- 在治疗前和治疗后的多个时间点收集的数据.
主要成果:
- 100%的阿尔茨海默病患者在基线时有S. aureus殖民.
- 在临床改善之前,dupilumab在第3天显著降低了金黄色细菌.
- 降低黄金色杆菌与降低CCL17,一种2型生物标志物相关,并改善了AD的严重程度.
结论:
- 用dupilumab阻止IL-4和IL-13信号传递,在AD患者中快速降低金黄色细菌.
- 黄金色细菌的减少与2型炎症标志物和临床严重程度的降低相关.
- 潜在的机制包括T H17细胞,中性粒细胞和补充通路.
关键词:
亚托邦性皮肤炎 (Atopic Dermatitis) 是一种不良的疾病.它们有IL-13和IL-13.它们的IL-17和IL-17.IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-IL-4-IL-4-IL-4-IL-4-IL-4-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL is is is is what is what is what is what is what is what is what is what is what is黄金葡萄球菌黄金葡萄球菌屏障障碍物 屏障障障碍物 屏障障障碍物细胞毒素 (cytotoxins) 是一种细胞毒素.双重复制的马布.微生物组是一个微生物组.第二种类型的免疫.相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
357
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Antiasthma Drugs: Leukotriene Modifiers
372
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
372


